Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 years or older~* Documented HIV-1 infection~* Stable PI regimen for at least 8 weeks prior to screening~* Plasma viral load at screening above 1000 HIV-1 RNA copies/ml~* Prior use of more than 1 NRTI for at least 3 months~* Prior use of one or more NNRTIs as part of a failing regimen~* At least 1 primary PI mutation as defined by the IAS guidelines~* Treatment with at least 1 PI for a total of at least 3 months~* Patient has given informed consent~Exclusion Criteria:~* Presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection~* Current or past history of alcohol and/or drug abuse which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures~* NNRTI as part of therapy at screening~* Patients on a treatment interruption at screening~* Patients for whom an investigational antiretroviral therapy is part of the regimen at screening or the use of any non-antiretroviral investigational agents 90 days prior to screening~* Hepatitis A, B, or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): TMC114/rtv 400mg TMC114/100mg rtv once daily
- 005 (Type: NO_INTERVENTION): Control Group Control Group, no intervention
- 004 (Type: EXPERIMENTAL): TMC114/rtv 600mg TMC114/100mg rtv twice daily
- 003 (Type: EXPERIMENTAL): TMC114/rtv 400mg TMC114/100mg rtv both twice daily
- 002 (Type: EXPERIMENTAL): TMC114/rtv 800mg TMC114/100mg rtv once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).